金属复合体在阿尔茨海默氏症疾病中的机制
Yi Liu1, Jiaying Ma1, Qianling Zhang2
1Guangdong Key Laboratory for Genome Stability & Disease Prevention, International Cancer Center, Department of Pharmacology, Shenzhen University Medical School, Shenzhen University, Shenzhen 518055, China.
International journal of molecular sciences
|November 27, 2024
概括
金属复合物通过准关键的病理特征显示出治疗阿尔茨海默病 (AD) 的前景. 本综述探讨了各种金属复合物及其潜在阻止AD进展的机制.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 材料科学 材料科学 材料科学
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,也是痴呆的主要原因,其特征是β-粉样蛋白斑块和神经纤维状结.
- 目前的阿尔茨海默病治疗只能提供有限的症状缓解,也不能阻止疾病的进展,这凸显了迫切需要新的治疗策略.
- 金属复合物正因其多方面的作用机制而成为阿尔茨海默病的有前途的治疗药物.
研究的目的:
- 审查目前用于阿尔茨海默病治疗的金属复合物的现状.
- 阐明金属复合体针对AD病理学的多种机制.
- 突出基于金属的药物在管理和潜在地治愈阿尔茨海默病的潜力.
主要方法:
- 对研究对阿尔茨海默病金属复合物的研究进行文献综述.
- 分析机制,包括抑制粉样β聚合和高酸化.
- 检查对突触功能和神经递质平衡的影响.
主要成果:
- 金属复合物,包括基于,白金,,,,铜和的复合物,显示出对抗AD的潜力.
- 这些复合物在抑制β-粉样蛋白聚合和细胞毒性方面表现出有效性.
- 它们还干扰蛋白病理学,调节神经递质系统.
结论:
- 金属复合体代表了阿尔茨海默病的有希望的治疗途径,提供了超越当前治疗的新机制.
- 对特定金属复合物的进一步研究可能会导致对AD的疾病修饰疗法的开发.
- 用金属复合物准多种病理途径可能为管理阿尔茨海默病提供更有效的策略.
相关概念视频
Alzheimer's Disease: Overview
448
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
448
Alzheimer's Disease: Treatment
165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165
Role of Neurotransmitters in Memory
436
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
436
Long-term Depression
2.5K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
Calcium Ion Concentration Mechanism
If over...
2.5K
Amyloid Fibrils
9.2K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.2K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
98
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
98


